1. Home
  2. GDL vs SKYE Comparison

GDL vs SKYE Comparison

Compare GDL & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GDL
    SELLHOLDBUYas of 15 hours ago
  • SKYE
    SELLHOLDBUYas of 15 hours ago
  • Stock Information
  • Founded
  • GDL 2006
  • SKYE 2012
  • Country
  • GDL United States
  • SKYE United States
  • Employees
  • GDL N/A
  • SKYE N/A
  • Industry
  • GDL Investment Managers
  • SKYE Biotechnology: Pharmaceutical Preparations
  • Sector
  • GDL Finance
  • SKYE Health Care
  • Exchange
  • GDL Nasdaq
  • SKYE Nasdaq
  • Market Cap
  • GDL 95.2M
  • SKYE 108.3M
  • IPO Year
  • GDL N/A
  • SKYE N/A
  • Fundamental
  • Price
  • GDL $7.94
  • SKYE $2.70
  • Analyst Decision
  • GDL
  • SKYE Buy
  • Analyst Count
  • GDL 0
  • SKYE 6
  • Target Price
  • GDL N/A
  • SKYE $18.67
  • AVG Volume (30 Days)
  • GDL 11.2K
  • SKYE 191.1K
  • Earning Date
  • GDL 01-01-0001
  • SKYE 02-09-2025
  • Dividend Yield
  • GDL 6.02%
  • SKYE N/A
  • EPS Growth
  • GDL N/A
  • SKYE N/A
  • EPS
  • GDL N/A
  • SKYE N/A
  • Revenue
  • GDL N/A
  • SKYE N/A
  • Revenue This Year
  • GDL N/A
  • SKYE N/A
  • Revenue Next Year
  • GDL N/A
  • SKYE N/A
  • P/E Ratio
  • GDL N/A
  • SKYE N/A
  • Revenue Growth
  • GDL N/A
  • SKYE N/A
  • 52 Week Low
  • GDL $7.65
  • SKYE $2.25
  • 52 Week High
  • GDL $8.13
  • SKYE $19.41
  • Technical
  • Relative Strength Index (RSI)
  • GDL 34.93
  • SKYE 25.41
  • Support Level
  • GDL $7.90
  • SKYE $3.21
  • Resistance Level
  • GDL $8.05
  • SKYE $3.55
  • Average True Range (ATR)
  • GDL 0.10
  • SKYE 0.40
  • MACD
  • GDL -0.01
  • SKYE -0.08
  • Stochastic Oscillator
  • GDL 15.93
  • SKYE 1.93

Stock Price Comparison Chart: GDL vs SKYE

GDL
SKYE
AprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober024681012141618GDL VS SKYE

About GDL GDL Fund The of Beneficial Interest

GDL Fund is a diversified closed-end management investment company. Its primary investment objective is to achieve absolute returns in various market conditions without excessive risk of capital. The fund seeks to achieve its objective by investing in merger arbitrage transactions and, to a lesser extent, in corporate reorganizations involving stubs, spin-offs, and liquidations.

About SKYE Skye Bioscience Inc. Common Stock

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Share on Social Networks:

By browsing this website, you accept our Privacy Policy & Terms of Use